Brief: AstraZeneca - Perioperative Imfinzi® (Durvalumab) Plus Neoadjuvant Enfortumab Vedotin Reduced Risk Of Recurrence By 49% And Risk Of Death By 42% In Muscle-Invasive Bladder Cancer
Today 15:36
BRIEF-AstraZeneca - Perioperative Imfinzi® (Durvalumab) Plus Neoadjuvant Enfortumab Vedotin Reduced Risk Of Recurrence By 49% And Risk Of Death By 42% In Muscle-Invasive Bladder Cancer Oct 24 (Reuters) - AstraZeneca PLC AZN.L:
PERIOPERATIVE IMFINZI® (DURVALUMAB) PLUS NEOADJUVANT ENFORTUMAB VEDOTIN REDUCED RISK OF RECURRENCE BY 49% AND RISK OF DEATH BY 42% IN MUSCLE-INVASIVE BLADDER CANCER
Source text: ID:nBw4pXQXla
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsBrief: AstraZeneca - Perioperative Imfinzi® (Durvalumab) Plus Neoadjuvant Enfortumab Vedotin Reduced Risk Of Recurrence By 49% And Risk Of Death By 42% In Muscle-Invasive Bladder Cancer
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Amgen drug combined with immunotherapy extends survival in lung cancer trial
Brief: AstraZeneca Says ZEGFROVY 200 Mg Administered Orally Once Daily Now Available In US
Factbox: Pharma sector doubles down on AI to slash costs, timelines